Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 50 min ago
Peer-reviewedCC BY-NC-ND 4.0Cell Reports Medicine

A blood-based metabolic signature for earlier detection of lung cancer

  • Ehsan Irajizad1
  • Hamid Khoshfekr Rudsari1
  • Sebastien Gendarme1,2
  • Jody Vykoukal3
  • Ranran Wu3
  • Jennifer B. Dennison3
  • Nastaran Karimi4
  • Faezeh Darbaniyan5
  • Seyed Javad Moghaddam4
  • Kim-Anh Do1
  • Ziding Feng6
  • Edwin Ostrin7
2 more authors
  • Samir Hanash3
  • Johannes F. Fahrmann3
7 affiliations
  1. 1Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  2. 2Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique–Hôpitaux de Paris, and Paris-Est Créteil University, Inserm, IMRB, Créteil, France
  3. 3Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  4. 4Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  5. 5Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  6. 6Biostatistics Program, Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  7. 7Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Read full textDOICite

Abstract

Metabolomic profiling was applied to 1,259 sera collected within five years of a lung cancer diagnosis and 8,470 non-case sera from ever-smoker participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to identify metabolic signatures for the earlier detection of lung cancer. We develop a panel of five lung cancer-associated metabolites (L5MetP: diacetylspermine, creatine riboside, arginine, hypoxanthine, and acylcarnitine C18:1) to assess 1-year risk of lung cancer. In the testing set, the L5MetP achieves an area under the receiver operating characteristic curve (AUC) of 0.79 (95% CI: 0.76–0.82) for 1-year risk of lung cancer. The L5MetP also complements existing clinical risk models that predict risk incident lung cancer as well as those that predict death from lung cancer. The L5MetP provides a means for identifying ever-smoker individuals who are lung cancer to inform on the need for lung cancer screening.

Related

  1. Cross-Tissue Concordance of a T1D Blood-Derived B-Cell Signature with Hashimoto Thyroiditis Tissue: Exploratory Spatial Immune-Topic Analysis
    Eun Young Joo, Sang Hun Lee
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
  2. Integrated transcriptomic analysis identifies an AKT1-associated metabolic-inflammatory signature in osteoporosis.
    Chenglong Bao, Ronggui Hu
    Clinical and experimental medicinePeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMC
  3. Identifying a Shared Metabolomic Signature in Mother–Newborn Dyads With and Without Gestational Diabetes: Implications for Early Metabolic Programming
    Isabel Omaña-Guzmán, Juan Carlos López-Alvarenga, Berenice Palacios-González +8
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
  4. Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines
    Anna C. Hogger, Ting Hong, Klaus Mantwill +3
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  5. Early detection of esophageal squamous cell carcinoma via a CACNA1E-SNTG1 cfDNA methylation signature.
    Chao Song, Jiyu Tang, Hailu Wu +10
    Clinical epigeneticsPeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMC

Cite

BibTeXRIS
BibTeX
@article{irajizad2026bloodbased,
  title = {{A blood-based metabolic signature for earlier detection of lung cancer}},
  author = {Ehsan Irajizad and Hamid Khoshfekr Rudsari and Sebastien Gendarme and Jody Vykoukal and Ranran Wu and Jennifer B. Dennison and Nastaran Karimi and Faezeh Darbaniyan and Seyed Javad Moghaddam and Kim-Anh Do and Ziding Feng and Edwin Ostrin and Samir Hanash and Johannes F. Fahrmann},
  journal = {Cell Reports Medicine},
  year = {2026},
  month = sep,
  doi = {10.1016/j.xcrm.2026.103059},
  url = {https://doi.org/10.1016/j.xcrm.2026.103059},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - A blood-based metabolic signature for earlier detection of lung cancer
AU  - Ehsan Irajizad
AU  - Hamid Khoshfekr Rudsari
AU  - Sebastien Gendarme
AU  - Jody Vykoukal
AU  - Ranran Wu
AU  - Jennifer B. Dennison
AU  - Nastaran Karimi
AU  - Faezeh Darbaniyan
AU  - Seyed Javad Moghaddam
AU  - Kim-Anh Do
AU  - Ziding Feng
AU  - Edwin Ostrin
AU  - Samir Hanash
AU  - Johannes F. Fahrmann
PY  - 2026
DA  - 2026/09/23
JO  - Cell Reports Medicine
DO  - 10.1016/j.xcrm.2026.103059
UR  - https://doi.org/10.1016/j.xcrm.2026.103059
AB  - Metabolomic profiling was applied to 1,259 sera collected within five years of a lung cancer diagnosis and 8,470 non-case sera from ever-smoker participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to identify metabolic signatures for the earlier detection of lung cancer. We develop a panel of five lung cancer-associated metabolites (L5MetP: diacetylspermine, creatine riboside, arginine, hypoxanthine, and acylcarnitine C18:1) to assess 1-year risk of lung cancer. In the testing set, the L5MetP achieves an area under the receiver operating characteristic curve (AUC) of 0.79 (95% CI: 0.76–0.82) for 1-year risk of lung cancer. The L5MetP also complements existing clinical risk models that predict risk incident lung cancer as well as those that predict death from lung cancer. The L5MetP provides a means for identifying ever-smoker individuals who are lung cancer to inform on the need for lung cancer screening.
SN  - 2666-3791
ER  -